Little difference seen in weight changes before, after COVID-19 shutdown
Jun 16, 2022
Significant increases were seen in weight during preshutdown and postshutdown years, but no significant difference was noted between the two.
COVID-19 vaccines cut mortality with heart failure
Jun 16, 2022
Those who are partially vaccinated and unvaccinated face the same increased risk, whereas boosted and fully vaccinated adults fare best.
More clinical benefits of molnupiravir ID’d in COVID-19
Jun 07, 2022
Compared with placebo, normalization of C-reactive protein and oxygen saturation was faster, with improvements seen on day 3 of treatment.
Operator error means some could miss out on $100,000 or more in Provider Relief Fund payments
By
Kimberly Bonvissuto
Jun 07, 2022
Provider error could mean the loss of $100,000 or more in Provider Relief Fund monies for some senior living organizations.
Sharing lessons from the pandemic
By
Lois A. Bowers
Jun 06, 2022
Brookdale Senior Living President and CEO Lucinda “Cindy” Baier discusses her new book, “Heroes Work Here: An Extraordinary Story of Courage, Resilience and Hope from the Front Lines of COVID-19.”
With questions about whether any further COVID-19 relief legislation will be passed this year, Argentum said Tuesday that it is focusing on a federal workplace safety rule, financial relief and workforce...
Multisystem abnormalities persist after COVID-19 hospitalization
May 31, 2022
Persisting evidence of cardio-renal involvement and hemostasis pathway activation was reported at 28 to 60 days after discharge.
U.S. making it easier to access COVID-19 treatment Paxlovid
May 27, 2022
The first test-to-treat site backed by the federal government is opening in Rhode Island.
COVID-19 can ‘rebound’ after treatment with Paxlovid, CDC says
May 24, 2022
In these cases, the illness improved or resolved within an average of three days.
Antibody levels after COVID-19 vaccination inversely linked to body weight
May 23, 2022
An inverse correlation was sustained for up to six months following two doses of BNT162b2 (Pfizer–BioNTech) in a small cohort of healthy young and middle-aged adults.